Michael Hofman‘s top 10 publications from 2024 which ProsTic contributed to
Michael Hofman, Nuclear Medicine Physician at Melbourne’s Peter MacCallum Cancer Centre and Director of ProsTic, shared on X:
“Very hard to pick but here are my top 10 publications from 2024 which team ProsTic contributed to:
1. (Jan’24, Lancet Oncol) TheraP follow-up: Lu-177 PSMA-617 vs cabazitaxel in mCRPC – OS ~similar, better QoL.
Authors: Michael S Hofman et al.
2. (Feb’24, J Nucl Med) CAIX-peptide first-in-human study – High tumor uptake and new theranostics potential.
Authors: Michael S. Hofman et al.
3. (Mar’24, Eur Urol) LuTectomy – Lu-177 PSMA-617 pre-RP in high-risk PCa – Safe, high radiation doses achieved.
Authors: Renu S. Eapen et al.
4. (Apr’24, Lancet) Commission – Surging PCa burden; calls for global strategies and research.
The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases
Authors: Nicholas D. James et al.
5. (May’24, Lancet Oncol) ENZA-p – Lu-177 PSMA-617 and enzalutamide – improved PFS in mCRPC.
Authors: Louise Emmett et al.
6. (Jun’24, Eur Urol) PSMA-PET in “nmCRPC” – Polymet disease – Worse survival vs conventional imaging.
Authors: Manuel Weber et al.
7. (Oct’24, Lancet Oncol) UpFrontPSMA – Lu-177 PSMA-617 – docetaxel in high-vol mHSPC – Superior antitumor activity.
Authors: Arun A. Azad et al.
8. (Oct’24, Eur Urol) APCCC – Expert consensus on advanced PCa imaging, therapy; highlights knowledge gaps.
Authors: Silke Gillessen et al.
9. (Nov’24, Lancet Oncol) Radiotherapy and Theranostics – Global disparities, need workforce expansion.
Radiotherapy and Theranostics: A Lancet Oncology Commission
Authors: May Abdel-Wahab et al.
10. (Nov 28’24, Eur Urol Oncol) proPSMA outcomes follow-up – Baseline PSMA-PET nodal status predicts failure in high-risk PCa.
Authors: Michael S. Hofman et al.
What a year in prostate theranostics!!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023